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Plasma omentin levels have been shown to be associated with circulating adiponectin con-
centrations and cardiometabolic disease-related outcomes. In this study, we aim to examine
the association of omentin gene polymorphism with serum adiponectin levels and cardiome-
tabolic health status using a genetic approach, and investigate whether these associations
are modified by lifestyle factors.
Methods
The study included 945 normal glucose tolerant and 941 unrelated individuals with type 2
diabetes randomly selected from the Chennai Urban Rural Epidemiology Study (CURES),
in southern India. Study participants were classified into cardiometabolically healthy and
unhealthy, where cardiometabolically healthy were those without hypertension, diabetes,
and dyslipidemia. Fasting serum adiponectin levels were measured by radioimmunoassay.
The omentin A326T (rs2274907) single nucleotide polymorphism (SNP) was screened by
polymerase chain reaction-restriction fragment length polymorphism and direct sequencing.
Results
The ‘A’ allele of the omentin SNP was significantly associated with lower adiponectin con-
centrations after adjusting for age, sex, body mass index (BMI), waist circumference (WC)
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and cardiometabolic health status (p = 1.90 x 10−47). There was also a significant associa-
tion between circulating adiponectin concentrations and cardiometabolic health status after
adjusting for age, sex, BMI, WC and Omentin SNP (p = 7.47x10-10). However, after adjust-
ing for age, sex, BMI, WC and adiponectin levels, the association of ‘A’ allele with cardiome-
tabolic health status disappeared (p = 0.79) suggesting that adiponectin serves as a
mediator of the association between omentin SNP and cardiometabolic health status. There
were no significant interactions between the SNP and dietary factors on adiponectin levels
and cardiometabolic health status (p>0.25, for all comparisons).
Conclusions
Our findings show that adiponectin might function as a mechanistic link between omentin
SNP and increased risk of cardiometabolic diseases independent of common and central
obesity in Asian Indians. Before strategies to promote adiponectin modulation could be
implemented, further studies are required to confirm the molecular mechanisms involved in
this triangular relationship between omentin gene, adiponectin and cardiometabolic
diseases.
Introduction
The prevalence of cardiometabolic diseases, such as type 2 diabetes (T2D), dyslipidemia, and
hypertension, is rapidly increasing in Asian Indians leading to increased morbidity and mor-
tality [1,2]. Despite lower body mass index (BMI), Asian Indians are characterised by increased
plasma insulin levels, insulin resistance, increased waist circumference, excess visceral fat,
lower high-density lipoprotein cholesterol (HDL-c), increased triglyceride levels and higher
proportion of small dense low-density lipoprotein cholesterol (LDL-c) [2,3]. In addition,
Asian Indians have low adiponectin levels [3], an adipokine with insulin-sensitizing, anti-apo-
ptotic, and anti-inflammatory properties, which has shown to play an important role in the
pathogenesis of dyslipidemia by affecting HDL-c and LDL-c metabolism [4–6].
Omentin, also referred as intelectin-1, is another adipocytokine that is highly expressed in
human visceral fat tissue [7]. In vitro and animal studies have shown that omentin enhances
insulin action in human adipocytes and has beneficial effects on cardiovascular system [8,9].
Majority of the studies have shown that circulating levels of omentin are decreased in individu-
als with obesity and T2D [10–13] and positively associated with flow-mediated vasodilatation
[14,15] suggesting a protective role of human omentin on cardiometabolic health. Even though
omentin and adiponectin have been shown to have anti-inflammatory and cardioprotective
effects, only a few studies have examined the physiological link between these adipokines in
relation to cardiometabolic diseases [16,17].
Several studies have demonstrated an association of omentin gene single nucleotide poly-
morphism (SNP), A326T (rs2274907), in the exon 4 with cardiometabolic disease-related
traits. A study in a South Asian population (N = 350) [18] has shown a significant association
between the SNP rs2274907 and coronary artery disease. In addition, a study in 168 Iranians
showed an association of this SNP with BMI and T2D [19]. Furthermore, a study in 495 Cen-
tral-Europeans showed that the T allele of the SNP rs2274907 was associated with lowest aver-
age energy intake (7877 ± 2780 J/day) [20]. However, a few small studies have failed to show a
significant association between the SNP and cardiometabolic traits [21,22], which could be
PLOS ONE Omentin, adiponectin and cardiometabolic health
PLOS ONE | https://doi.org/10.1371/journal.pone.0238555 May 12, 2021 2 / 15
either due to insufficient statistical power or differences in genetic heterogeneity. To date,
there are no genetic studies to establish the triangular molecular link between omentin, adipo-
nectin and cardiometabolic health status. Given that genetic associations are less prone to con-
founding [23,24], in the present study, we have used an extensively studied missense
polymorphism, rs2274907, in the omentin gene, as a genetic instrument to test for its associa-
tion with serum adiponectin levels and cardiometabolic health status in up to 1,886 individuals
from an Asian Indian population. In addition, we have tested for the interaction of this genetic




The study participants were chosen from the urban component of the Chennai Urban Rural
Epidemiology Study (CURES), a cross-sectional epidemiological study conducted on a repre-
sentative sample of the population of Chennai in Southern India [25]. The details of the study
has been published elsewhere [25] and is briefly outlined in Fig 1. Briefly, in phase 1, 26,001
individuals were recruited based on a systematic random sampling technique. Participants
with self-reported diabetes taking drug treatment for diabetes were classified as “known diabe-
tes”. All individuals with known diabetes (n = 1,529) were invited to visit the center for
detailed studies. In addition, every 10th individual of the 26,001 individuals without known
diabetes was invited to undergo oral glucose tolerance tests using a 75-g oral glucose load (dis-
solved in 250 ml of water) (Phase 3 of CURES). Those who were confirmed by oral glucose tol-
erance test to have 2-h plasma glucose value� 11.1 mmol/l (200 mg/dl) based on World
Fig 1. Flow diagram describing the selection of study participants. The Chennai Urban Rural Epidemiology Study
(CURES) is a large ongoing epidemiological study on a representative population of Chennai. Briefly, the city of
Chennai is divided into 155 corporation wards representing a socioeconomically diverse group. In Phase 1 of CURES,
individuals from 46 corporation wards were screened by a systematic sampling technique. The sample distribution in
each ward within these zones is based on the proportion of their population in that zone. A probabilistic proportionate
sampling was adopted to select the number of individuals seen in each ward. Furthermore, within each ward, every
third lane or road, following the right-hand rule, was surveyed. A total of 26,001 individuals aged�20 years were
screened. Phase 2 of CURES deals with studies on the prevalence of microvascular and macrovascular complications of
diabetes in subjects with self-reported diabetes from Phase 1 of the study. In Phase 3 of CURES, every tenth subject
recruited in Phase 1 (n = 2,600), was invited to the tertiary care centre for diabetes for an OGTT; known diabetic
subjects had fasting and postprandial glucose tests. For the current article, analysis was computed in randomly selected
941 individuals with diabetes from Phase 2 and 945 individuals with normal glucose tolerance from Phase 3, totalling
to 1,886 individuals.
https://doi.org/10.1371/journal.pone.0238555.g001
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Health Organization (WHO) consulting group criteria were labelled as “newly detected diabe-
tes” and those with 2-h plasma glucose value< 7.8 mmol/l (140 mg/dl) as being normal glu-
cose tolerant (NGT) [26]. For the present study, 945 NGT and 941 unrelated individuals with
T2D and genetic data were included. Written informed consent was obtained from all study
participants, and the study was approved by the Madras Diabetes Research Foundation Institu-
tional Ethics Committee. There were no minors involved in the study.
Phenotype measurements
Anthropometric measurements including weight, height, and waist circumference (WC) were
obtained using standardized techniques. The BMI was calculated as weight (in kg) divided by
the square of height (in m). Blood pressure was recorded in the sitting position in the right
arm to the nearest 2mmHg using the mercury sphygmomanometer (Diamond Deluxe BP
apparatus, Pune, India). Two readings were taken 5 minutes apart and mean of two was taken
as the blood pressure.
Venous blood samples were collected in EDTA-containing vacutainer tubes (for plasma
and whole blood) and plain tubes without additives (for serum) by experienced phleboto-
mists in all participants for biochemical and genetic analyses. Whole blood samples were
aliquoted in port tubes and stored in a deep freezer at −20˚C for genetic analysis. The
remaining blood samples collected in the EDTA and plain tubes were centrifuged to sepa-
rate the plasma and serum within 1 hour of collection. After measurement of biochemical
parameters on the day of blood sample collection, the remaining serum and plasma were
aliquoted into cryotubes and stored in a deep freezer at −80˚C for future research analysis.
Biochemical analyses were done on a Hitachi-912 Auto Analyzer (Hitachi, Mannheim,
Germany) using kits supplied by Roche Diagnostics (Mannheim). Fasting plasma glucose
(glucose oxidase–peroxidase method), serum cholesterol (cholesterol oxidase-phenol-
4-amino-antipyrene peroxidase method), serum triglycerides (glycerol phosphatase oxi-
dase-phenol-4-amino-antipyrene peroxidase method), and HDL-c (direct method; poly-
ethylene glycol-pretreated enzymes) were measured. LDL-c was calculated using the
Friedewald formula [27]. Glycated haemoglobin (HbA1c) was estimated by high-perfor-
mance liquid chromatography using a Variant™ machine (Bio-Rad, Hercules, CA, USA).
Serum insulin concentration was estimated using an enzyme-linked immunosorbent assay
(Dako, Glostrup, Denmark).
Assessment of serum adiponectin concentrations
Fasting adiponectin levels were measured using radioimmunoassay (Cat. No. HADP-61HK,
Linco Research, St Charles, MO, USA). The intra-assay and the inter-assay co-efficient of vari-
ation were 3.8 and 7.4 per cent respectively and the lower detection limit was 1 ng/ml [28].
Adiponectin data was available for 1,205 samples.
Dietary intake and physical activity assessments
Dietary intakes were assessed using a previously validated and published [29] interviewer
administered semi-quantitative food frequency questionnaire (FFQ) containing 222 food
items to estimate food intake over the past year. A detailed description of the development
of FFQ and the data on reproducibility and validity had been published [29]. A validated
self-report questionnaire was used to measure physical activity [30]. For the present
study, only a subset of the study population (N = 513) had data on dietary intake and
physical activity.
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Definitions
Study participants were classified into cardiometabolically healthy (N = 370) and unhealthy
(N = 1,516), where cardiometabolically healthy were those without hypertension, diabetes, and
dyslipidemia [31]. Hypertension was diagnosed in all subjects who were on drug treatment for
hypertension or if the blood pressure� 140/90 mmHg [32]. National Cholesterol Education
Programme guidelines were used to define those with and without dyslipidemia [33].
SNP genotyping
The SNPrs2274907 was genotyped by polymerase chain reaction on a GeneAmp PCR system
9700 thermal cycler (Applied Biosystems, Foster City, CA) using the primers, forward: 5ˈ CCT
CTGCAGATCCAAAGGTG 3ˈ and reverse: 5ˈ CCGCACTGAGAATGGTGTTA 3ˈ. The PCR
amplicons were digested with AccI restriction enzyme (New England Biolabs, Inc., Beverly,
MA) and the resulting products were electrophoresed on a 3% agarose gel (S1 Fig). Based on
the analysis of 200 blind duplicates (20%), there was 100% concordance in the genotyping.
Furthermore, a few variants were confirmed by direct sequencing with an ABI 310 genetic ana-
lyzer (Foster City, CA). The SNP was in Hardy Weinberg equilibrium (HWE) (P = 0.59).
Statistical analyses
Descriptive statistics are presented as means and SD for continuous variables and as percent-
ages for categorical variables. To test whether the observed genotype counts were in HWE, a
goodness-of-fit chi-square test was performed. Student t test as appropriate was used to com-
pare groups for continuous variables. Given the low frequency of the rare homozygotes, domi-
nant model was used (comparing individuals with common homozygous genotypes with the
combined group of rare homozygotes and heterozygotes). The genetic associations with the
continuous and categorical outcomes were examined using linear and logistic regression mod-
els, respectively, adjusting for age, sex, BMI and serum adiponectin, wherever appropriate.
Interactions between the SNP and dietary intake were assessed by including an interaction
term in the linear and logistic regressions. All analyses were carried out using SPSS, version 26.
A P value<0.05 was considered to be statistically significant.
Power calculation
Given that there are no previously reported effect sizes for the associations and interactions
pertaining to the Omentin SNP and adiponectin concentrations in the Asian Indian popula-
tion, we were unable to perform a prospective power calculation. However, based on the most
significant associations observed in the present study, we performed a retrospective power cal-
culation using QUANTO software, Version 1.2.4 (May 2009). We performed power calcula-
tions in the form of least detectable effects based on the assumption of significance levels and
powers of 5 and 80%, respectively. At 80% power, the minimum detectable effect was beta
1.50 μg/mL (adiponectin concentrations) for a SNP with minor allele frequency of 21% in the
case-control analysis (N = 1,204).
Results
Associations between cardiometabolic health status and clinical and
biochemical parameters
In the present study, 80.3% of the individuals were cardiometabolically unhealthy with signifi-
cantly higher BMI, WC, fasting plasma glucose, insulin, total serum cholesterol, LDL-c,
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triglycerides, systolic and diastolic blood pressures and HbA1c and lower HDL-c and serum
adiponectin concentrations (p<9.6 x 10−9 for all comparisons) (Table 1).
There was a significant association between circulating adiponectin concentrations and car-
diometabolic health status after adjusting for age, sex, BMI, WC and Omentin SNP rs2274907,
where cardiometabolically unhealthy individuals had 2.00 μg/mL decrease in adiponectin con-
centrations compared to the control group (p = 7.47x10-10).
Association between the SNP and serum adiponectin concentrations
The Omentin SNP rs2274907 was significantly associated with serum adiponectin concentra-
tions after adjusting for age, sex, BMI, WC and cardiometabolic health status (p = 1.90 x
10−47), where ‘A’ allele carriers (AT + AA) had significantly lower levels of adiponectin
(means ± SE: 4.2 ± 2.7 μg/mL) compared to those with TT genotype (means ± SE: 8.9 ± 4.5 μg/
mL) (Fig 2).
Association between the SNP and cardiometabolic health status
After adjusting for age, sex, BMI and WC, there was a significant association between the ‘A’
allele of the SNP rs2274907 and increased risk of cardiometabolic health status, where ‘A’ allele
carriers had 1.35 times increased risk of being cardiometabolically unhealthy compared to TT
Table 1. Clinical and biochemical characteristics of the participants from the CURES study.





Age (years) 37±13 47±13 3.41 x 10−36
Sex (men/women) 111/259 736/780 1.27 x
10−10��
Body mass index (kg/m2) 22.1±4.8 24.9±4.4 3.39 x 10−22
Waist circumference (cm) 79±12 89±11 1.58 x 10−41
Waist-hip ratio 0.85±0.09 0.92±0.08 1.32 x 10−49
Fasting plasma glucose (mg/dl) 84±8 134±67 1.30 x 10−146
Fasting serum insulin (μIU/ml) 7.6±5.2 10.1±6.5 4.33 x 10−13
Systolic blood pressure (mmHg) 116±16 126±20 5.46 x 10−24
Diastolic blood pressure (mmHg) 73±10 77±11 2.77 x 10−9
Total serum cholesterol (mg/dl) 162±20 196±43 3.20 x 10−92
Serum triglycerides (mg/dl) 79±25 163±109 4.68 x 10−137
Low-density lipoprotein cholesterol (mg/dl) 97±18 122±37 6.55 x 10−72
High-density lipoprotein cholesterol (mg/dl) 50±7 41±10 5.98 x 10−61
Glycated hemoglobin (%) 5.5±0.4 7.6±2.4 7.23 x 10−179
Fasting serum adiponectin (μg/mL) 9.9±5.6 7.4±4.3 9.60 x 10−9
Total energy intake (kcal) 2655±579 2813±919 0.12
Carbohydrate energy (%) 65±7 65±6 0.97
Protein energy (%) 11±1 11±1 0.35
Fat energy (%) 23±5 23±5 0.47
Fibre (g/day) 30±8 33±12 0.07
Physical activity levels (Sedentary %/ Moderately active %/
Physically active %)
81/ 18/ 1 82/ 15/ 3 0.52��
Data shown are represented as means ± SD, wherever appropriate.
�P values generated from an independent samples ‘t’ test for the differences in the means/proportions between cardiometabolically healthy and unhealthy participants.
�� P value generated from a chi-square test.
https://doi.org/10.1371/journal.pone.0238555.t001
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homozygotes (p = 0.03). However, after adjusting for age, sex, BMI, WC and adiponectin con-
centrations, the ‘A’ allele was not associated with cardiometabolic health status (P = 0.79) (Fig 3).
There was also no significant difference in the genotype and allele frequencies of the SNP
between cardiometabolically unhealthy and healthy individuals under an additive (p = 0.31)
and a dominant (p = 0.40) model (S1 Table).
Interaction between SNP and adiponectin concentrations on
cardiometabolic health status
To test if the association between the SNP and cardiometabolic health status is modified by
serum adiponectin concentrations, we examined the interaction between the SNP and
Fig 2. Association between omentin SNP rs2274907 with serum adiponectin concentrations. After adjusting for
age, sex, BMI, WC and cardiometabolic health status, the ‘A’ allele carriers (AA + AT) have significantly lower levels of
serum adiponectin concentrations compared to those with TT genotype (p = 1.90 x 10−47). Abbreviations: BMI, Body
mass index; WC, waist circumference; SNP, Single nucleotide polymorphism.
https://doi.org/10.1371/journal.pone.0238555.g002
Fig 3. Diagram showing the role of circulating adiponectin as an intermediate predictor between omentin SNP
and cardiometabolic health status. One-sided arrows with unbroken lines represent significant associations and one-
sided arrows with broken lines represent lack of associations. There is a significant association between the omentin
SNP rs2274907 and lower serum adiponectin concentrations after adjusting for age, sex, BMI, WC and
cardiometabolic health status (p = 1.90 x 10−47). There is a significant association between serum adiponectin
concentrations and cardiometabolic health status after adjusting for age, sex, BMI, WC and SNP rs2274907
(p = 7.47x10-10). There is no association between the omentin SNP rs2274907 and cardiometabolic health status after
adjusting for age, sex, BMI, WC and serum adiponectin concentrations (p = 0.79). Abbreviations: BMI, Body mass
index; WC, waist circumference; SNP, Single nucleotide polymorphism.
https://doi.org/10.1371/journal.pone.0238555.g003
PLOS ONE Omentin, adiponectin and cardiometabolic health
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adiponectin on cardiometabolic health status. There was no evidence for a significant interac-
tion (pinteraction = 0.24) suggesting that adiponectin is unlikely to modify the effect of the SNP
on cardiometabolic health status.
Interaction between SNP and lifestyle factors on adiponectin
concentrations and cardiometabolic health status
There was no significant interaction between the SNP and lifestyle factors such as carbohy-
drate energy %, fat energy %, protein energy %, dietary fibre intake and physical activity levels
on adiponectin concentrations and cardiometabolic health status (P>0.25, for all compari-
sons), respectively (Table 2).
Discussion
Our study provides the first evidence for the role of circulating adiponectin as a mechanistic
link in the association between omentin SNP rs2274907 and cardiometabolic health indepen-
dent of common and central obesity in this Asian Indian population. In this study, we
observed a strong cross-sectional association between the omentin SNP and serum adiponec-
tin concentrations, even after accounting for the potential confounders including cardiometa-
bolic health status. Similarly, a strong association was seen between adiponectin
concentrations and cardiometabolic health status after adjusting for the confounders including
the omentin SNP. However, the association between ‘A’ allele of the omentin SNP rs2274907
and cardiometabolic health disappeared after adjusting for serum adiponectin concentrations,
which suggests that the association is likely to be mediated through circulating adiponectin.
Hence, modulating adiponectin concentrations through lifestyle interventions might be an
effective approach to overcome the genetic risk of cardiometabolic diseases.
Adiponectin, an adipokine with 244 amino acids, is synthesized by adipocytes and has been
shown to stimulate the glucose uptake in skeletal muscles and decrease the hepatic glucose syn-
thesis [34], whereas omentin, a 313-amino-acid-long polypeptide adipokine, is mainly synthe-
sized by visceral adipose tissue and is involved in cellular energy homoeostasis and vascular
tone regulation [8]. Both animal and human studies have demonstrated a positive correlation
between omentin and adiponectin concentrations [12,35–37]. However, there is no study, to
date, that has examined the genetic variants in omentin gene with serum adiponectin concen-
trations. The present study has examined the A326T (SNP rs2274907), which is a single nucle-
otide missense polymorphism in the exon-4 of the Omentin 1 gene, which substitutes valine
instead of aspartic acid at position 109 (Val109Asp or V109D). Even though the position 109 is
located outside the fibrinogen domain of Omentin protein, several studies have reported
Table 2. Interactions between the Omentin SNP rs2274907 and lifestyle factors on adiponectin concentrations and cardiometabolic health status.
P values for the interactions between the Omentin SNP and dietary factors on serum adiponectin concentrations��
SNP�Carbohydrate energy % SNP�Protein energy % SNP�Fat energy % SNP�Fibre (g) C SNP�physical activity
0.77 0.37 0.57 0.98 0.95
P values for the interactions between the Omentin SNP and dietary factors on cardiometabolic health status���
SNP�Carbohydrate energy % SNP�Protein energy % SNP�Fat energy % SNP�Fibre (g) C SNP�physical activity
0.87 0.26 0.14 0.30 0.69
��P values obtained from linear regression analysis after adjusting for age, sex, body mass index, waist circumference and cardiometabolic health status.
��� Data are p values obtained from logistic regression analysis after adjusting for age, sex, body mass index, waist circumference and adiponectin concentrations.
C Adjusted for age, sex, body mass index, waist circumference, adiponectin concentrations and total energy intake.
SNP, Single Nucleotide Polymorphism.
https://doi.org/10.1371/journal.pone.0238555.t002
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association of the SNP rs2274907 with cardiometabolic diseases [18–22,38] suggesting that the
SNP might be in linkage disequilibrium (LD) with another causative variant. Interestingly, a
study in 4,200 North Indians that had examined 207 common genetic variants in proximal
promoter and untranslated regions of genes on 1q21–23 and 20q13 identified omentin SNP
rs1333062 as one of the top signals for T2D [38]; this SNP in the 3’ flank region of omentin
gene is in complete LD with Val109Asp—SNP rs2274907 (D’ = 1.0 and r2 = 1.0 for Gujarati
Indians in Houston, Texas population from HapMap data). Although the amino acid position
109 does not represent a completely conserved consensus position [5], the direct adjacent site
at 108 contains a highly conserved amino acid (alanine) and hence, the proximity of the substi-
tuted amino acid at 109 position to the highly conserved amino acid at 108 might be of func-
tional relevance.
Our study has shown that the minor ‘A’ allele of the omentin SNP rs2274907 is associated
with cardiometabolic health under the mediation of circulating adiponectin levels. The effect
of the minor allele on chronic disease outcomes has also been demonstrated in other ethnic
groups including Pakistani (N = 350) [18], Iranian (N = 168 & 282) [22,39] and Turkish
(N = 87) [40] populations. However, a couple of small studies, one in a Caucasian population
(N = 390) and one in an Indian population (N = 500) [41], failed to provide an evidence of an
association of the SNP with T2D [21]. These discrepancies are likely to be due to the existence
of genetic heterogeneity across different ethnic groups and insufficient statistical power to
detect small effect sizes. To date, the present study has been the largest (N = 1,886) to explore
the association of the omentin SNP rs2274907 with cardiometabolic diseases. While majority
of the studies have shown ‘T’ allele as the minor allele [18,22,39,40], the dbSNP database shows
‘A’ allele as the minor allele except for some of the Asian, African and European populations,
which is indicative of a significant genetic heterogeneity (https://www.ncbi.nlm.nih.gov/
projects/SNP/snp_ref.cgi?do_not_redirect&rs=rs2274907) [42]. However, ‘A’ allele is the
minor allele in our study and the dbSNP database for GIH population (Gujarati Indians in
Houston, Texas, USA). This suggests that future large studies focusing on omentin SNP
rs2274907 is highly warranted in each ethnic group to understand the ethnic-specific role of
the variant in cardiometabolic diseases.
Several studies have implicated hypoadiponectinemia in the pathogenesis of T2D and car-
diovascular diseases [43–45]. Higher concentrations of adiponectin have been shown to
decrease the cardiometabolic risk [46,47], given its role in promoting anti-inflammatory
effects, improving insulin sensitivity, increasing glucose uptake by the cells and producing
endothelial nitric oxide [48,49]. While some studies have shown adiponectin as an indepen-
dent risk factor for cardiometabolic diseases [44,50], there are a few studies that have shown
adiponectin as a mediator of the cross-talk between adipose tissue and cardiovascular system
[51]. Furthermore, a few studies have also explained the role of adiponectin as a mediator in
the relationship between omentin and cardiometabolic diseases [35,52]. These studies suggest
that omentin could be classified under the growing group of adipokines including adiponectin
which might have cardioprotective effects [53]. These mechanistic studies are in line with our
genetic association study in Asian Indians, where circulating adiponectin levels seem to serve
as a mediator in conferring the genetic risk of cardiometabolic diseases. A previous study in a
Spanish population has shown a significant association of the minor allele of the omentin SNP
rs12409609, which is in complete LD with SNP rs2274907, with low omentin gene expression
[54]. Given the positive correlation between plasma omentin and adiponectin levels [12,35–
37], it is possible that low omentin expression might contribute to the reduction in adiponectin
levels, which, in turn, could possibly increase the cardiometabolic risk among ‘A’ allele carri-
ers. However, mechanistic studies are required to confirm the triangular relationship between
omentin gene, adiponectin and cardiometabolic risk.
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Our study findings are suggestive of the fact that modulation of adiponectin levels might be
an effective strategy to overcome the genetic risk of cardiometabolic diseases. Previous studies
have examined the impact of lifestyle modifications and drug therapies to improve the circulat-
ing adiponectin concentrations [55–57]. A few studies have shown that weight loss [58] and
combined diet control and physical exercise [59] can increase plasma levels of adiponectin,
while smoking [60] and increasing activity of the sympathetic nervous system [61] can
decrease the adiponectin concentrations. Drugs such as renin-angiotensin system blocking
agents [62], peroxisome proliferator activated receptor (PPAR)-alpha agonists [63], PPAR-
gamma agonists [64] and hypoglycemic drugs [65] have been shown to improve adiponectin
concentrations. To understand whether modifying the lifestyle could overcome the genetic
risk of hypoadiponectinemia and cardiometabolic diseases, we investigated the SNP-lifestyle
interactions and found that none of the interactions were statistically significant. The lack of
interaction could be a result of the small sample size and insufficient statistical power to detect
the small effect sizes of the interactions.
The main strength of the study is the large sample size from a well characterised population,
which is representative of the city of Chennai, and the study is sufficiently powered to detect
the genetic associations. The other strength is the use of a validated FFQ, which has shown
high reproducibility and validity for total carbohydrates and dietary fibre. However, our study
has a few limitations which need to be acknowledged. We performed a cross-sectional study
and hence, we are unable to infer causality between the SNP, adiponectin concentrations and
cardiometabolic disease outcomes. Furthermore, as the study is based on 1,886 randomly
selected diabetic participants and those with NGT, extrapolating these results to the general
population should be done with caution. However, the selection process has ensured that the
study subjects are representative of the population. Although confounders were adjusted in
our regression analyses, we cannot exclude the residual confounding due to unknown factors.
Another limitation is the recall bias from FFQ which cannot be ruled out. Even though our
study is sufficiently powered to detect the genetic associations, the sample size is small for
detecting significant gene-lifestyle interactions, which might be the reason for the lack of sig-
nificant interactions. Furthermore, omentin protein or mRNA expression levels were not
assessed in the study and hence, it is not possible to confirm whether the SNP has any influ-
ence on the omentin gene expression. Finally, given that the outcome is a multifactorial trait,
the present study has examined only one genetic variant from the omentin gene; however, this
is the only coding region variant that has been extensively studied in the gene. Future studies
should focus on using a tagSNP approach which will be an effective strategy for the study of
genetic level variation of complex diseases such as cardiometabolic traits [66].
In summary, we have identified a robust association between the omentin SNP and serum
adiponectin concentrations and the latter with cardiometabolic disease outcomes, suggesting
that adiponectin could be a pathogenic mediator of the genetic susceptibility towards cardio-
metabolic disease outcomes. These findings suggest that targeting adiponectin might be bene-
ficial in overcoming the genetic risk of cardiometabolic diseases. Hence, lifestyle interventions
and drug therapies to increase adiponectin levels could serve as effective tools in preventing
cardiometabolic diseases in Asian Indians. However, mechanistic studies are required to con-
firm this epidemiological relationship before strategies to promote adiponectin modulation
could be implemented.
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